MDxHealth SA (NAS:MDXH)

Q1 2026 MDxHealth SA Earnings Call Transcript

May 13, 2026 / 08:30 PM GMT

Release Date Price: $1.95 (+4.28%)

Transcript

Key Points

Positve

MDxHealth SA (MDXH) achieved significant revenue growth from $11 million in 2019 to $108 million in 2025.
The company improved its gross margins from the 20s to the mid-60s, reaching adjusted EBITDA profitability prior to acquiring the EXODX business.
MDxHealth SA (MDXH) is focusing on its core prostate cancer precision diagnostics, which is expected to drive scalable value.
The company has initiated an AI-dedicated strategic initiative to enhance operating efficiency and maximize clinical value.
MDxHealth SA (MDXH) reported a solid balance sheet with cash and cash equivalents totaling $43.2 million as of March 31, 2026.

Negative

MDxHealth SA (MDXH) decided to discontinue its Resolve UTI offering due to an uncertain reimbursement landscape.
The company received a communication from Novitas seeking up to $10.4 million in recoupments of historical resolved testing claims.
MDxHealth SA (MDXH) reported a pro forma operating loss of $7.9 million for the quarter, compared to a pro forma operating loss of $4.7 million for the prior year.
The statutory as-reported net loss was $8.9 million, with a pro forma net loss of $9.4 million.
The company anticipates potential restructuring expenses related to ceasing operations at its laboratory facility in Plano, Texas.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

MDXH.OQ - MDxHealth SA
Q1 2026 MDxHealth SA Earnings Call
May 13, 2026 / 08:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Please stand by, your meeting is about to begin.

Good afternoon, everyone, and welcome to today's MDX Health first quarter 2026 earnings conference call. At this time, all participants are in a listen-only mode. Later, you will have the opportunity to ask questions during the question-and-answer session. To register to ask a question at any time, please press star one on your telephone. To remove yourself from the queue, press star two. Please note, today's call is being recorded, and it is now my pleasure to turn the meeting over to Mr. John Francis. Please go ahead, sir.

--------------------------------------------------------------------------------
Unidentified_2 [2]
----------------------------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.